2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Interleukin-16 is increased in obesity and alters adipogenesis and inflammation in vitro

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Obesity is a chronic condition associated with low-grade inflammation mainly due to immune cell infiltration of white adipose tissue (WAT). WAT is distributed into two main depots: subcutaneous WAT (sWAT) and visceral WAT (vWAT), each with different biochemical features and metabolic roles. Proinflammatory cytokines including interleukin (IL)-16 are secreted by both adipocytes and infiltrated immune cells to upregulate inflammation. IL-16 has been widely studied in the peripheral proinflammatory immune response; however, little is known about its role in adipocytes in the context of obesity.

          Aim & Methods

          We aimed to study the levels of IL-16 in WAT derived from sWAT and vWAT depots of humans with obesity and the role of this cytokine in palmitate-exposed 3T3-L1 adipocytes.

          Results

          The results demonstrated that IL-16 expression was higher in vWAT compared with sWAT in individuals with obesity. In addition, IL-16 serum levels were higher in patients with obesity compared with normal-weight individuals, increased at 6 months after bariatric surgery, and at 12 months after surgery decreased to levels similar to before the intervention. Our in vitro models showed that IL-16 could modulate markers of adipogenesis (Pref1), lipid metabolism (Plin1, Cd36, and Glut4), fibrosis (Hif1a, Col4a, Col6a, and Vegf), and inflammatory signaling (IL6) during adipogenesis and in mature adipocytes. In addition, lipid accumulation and glycerol release assays suggested lipolysis alteration.

          Discussion

          Our results suggest a potential role of IL-16 in adipogenesis, lipid and glucose homeostasis, fibrosis, and inflammation in an obesity context.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

          Visceral adipose tissue (VAT) compartments may confer increased metabolic risk. The incremental utility of measuring both visceral and subcutaneous abdominal adipose tissue (SAT) in association with metabolic risk factors and underlying heritability has not been well described in a population-based setting. Participants (n=3001) were drawn from the Framingham Heart Study (48% women; mean age, 50 years), were free of clinical cardiovascular disease, and underwent multidetector computed tomography assessment of SAT and VAT volumes between 2002 and 2005. Metabolic risk factors were examined in relation to increments of SAT and VAT after multivariable adjustment. Heritability was calculated using variance-components analysis. Among both women and men, SAT and VAT were significantly associated with blood pressure, fasting plasma glucose, triglycerides, and high-density lipoprotein cholesterol and with increased odds of hypertension, impaired fasting glucose, diabetes mellitus, and metabolic syndrome (P range < 0.01). In women, relations between VAT and risk factors were consistently stronger than in men. However, VAT was more strongly correlated with most metabolic risk factors than was SAT. For example, among women and men, both SAT and VAT were associated with increased odds of metabolic syndrome. In women, the odds ratio (OR) of metabolic syndrome per 1-standard deviation increase in VAT (OR, 4.7) was stronger than that for SAT (OR, 3.0; P for difference between SAT and VAT < 0.0001); similar differences were noted for men (OR for VAT, 4.2; OR for SAT, 2.5). Furthermore, VAT but not SAT contributed significantly to risk factor variation after adjustment for body mass index and waist circumference (P < or = 0.01). Among overweight and obese individuals, the prevalence of hypertension, impaired fasting glucose, and metabolic syndrome increased linearly and significantly across increasing VAT quartiles. Heritability values for SAT and VAT were 57% and 36%, respectively. Although both SAT and VAT are correlated with metabolic risk factors, VAT remains more strongly associated with an adverse metabolic risk profile even after accounting for standard anthropometric indexes. Our findings are consistent with the hypothesized role of visceral fat as a unique, pathogenic fat depot. Measurement of VAT may provide a more complete understanding of metabolic risk associated with variation in fat distribution.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

            Summary Background The main associations of body-mass index (BMI) with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people. The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies. Methods Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 894 576 participants, mostly in western Europe and North America (61% [n=541 452] male, mean recruitment age 46 [SD 11] years, median recruitment year 1979 [IQR 1975–85], mean BMI 25 [SD 4] kg/m2). The analyses were adjusted for age, sex, smoking status, and study. To limit reverse causality, the first 5 years of follow-up were excluded, leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other. Findings In both sexes, mortality was lowest at about 22·5–25 kg/m2. Above this range, positive associations were recorded for several specific causes and inverse associations for none, the absolute excess risks for higher BMI and smoking were roughly additive, and each 5 kg/m2 higher BMI was on average associated with about 30% higher overall mortality (hazard ratio per 5 kg/m2 [HR] 1·29 [95% CI 1·27–1·32]): 40% for vascular mortality (HR 1·41 [1·37–1·45]); 60–120% for diabetic, renal, and hepatic mortality (HRs 2·16 [1·89–2·46], 1·59 [1·27–1·99], and 1·82 [1·59–2·09], respectively); 10% for neoplastic mortality (HR 1·10 [1·06–1·15]); and 20% for respiratory and for all other mortality (HRs 1·20 [1·07–1·34] and 1·20 [1·16–1·25], respectively). Below the range 22·5–25 kg/m2, BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer. These inverse associations were much stronger for smokers than for non-smokers, despite cigarette consumption per smoker varying little with BMI. Interpretation Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22·5–25 kg/m2. The progressive excess mortality above this range is due mainly to vascular disease and is probably largely causal. At 30–35 kg/m2, median survival is reduced by 2–4 years; at 40–45 kg/m2, it is reduced by 8–10 years (which is comparable with the effects of smoking). The definite excess mortality below 22·5 kg/m2 is due mainly to smoking-related diseases, and is not fully explained. Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, EU BIOMED programme, US National Institute on Aging, and Clinical Trial Service Unit (Oxford, UK).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation

              This paper considers the argument for obesity as a chronic relapsing disease process. Obesity is viewed from an epidemiological model, with an agent affecting the host and producing disease. Food is the primary agent, particularly foods that are high in energy density such as fat, or in sugar-sweetened beverages. An abundance of food, low physical activity and several other environmental factors interact with the genetic susceptibility of the host to produce positive energy balance. The majority of this excess energy is stored as fat in enlarged, and often more numerous fat cells, but some lipid may infiltrate other organs such as the liver (ectopic fat). The enlarged fat cells and ectopic fat produce and secrete a variety of metabolic, hormonal and inflammatory products that produce damage in organs such as the arteries, heart, liver, muscle and pancreas. The magnitude of the obesity and its adverse effects in individuals may relate to the virulence or toxicity of the environment and its interaction with the host. Thus, obesity fits the epidemiological model of a disease process except that the toxic or pathological agent is food rather than a microbe. Reversing obesity will prevent most of its detrimental effects.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/2664952Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/2590977Role: Role: Role: Role:
                Role: Role:
                Role:
                Role: Role:
                Role: Role:
                Role: Role:
                Role: Role:
                URI : https://loop.frontiersin.org/people/1981184Role: Role:
                URI : https://loop.frontiersin.org/people/964200Role: Role: Role:
                URI : https://loop.frontiersin.org/people/1756839Role:
                URI : https://loop.frontiersin.org/people/1221187Role: Role: Role: Role: Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/567583Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role:
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                13 March 2024
                2024
                : 15
                : 1346317
                Affiliations
                [1] 1 Endocrinology department, Germans Trias i Pujol Research Institute (IGTP) , Badalona, Spain
                [2] 2 Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona (UB) , Barcelona, Spain
                [3] 3 Department of Basic Health Sciences, University Rey Juan Carlos (URJC) , Madrid, Spain
                [4] 4 Pediatric Surgery Department, Hospital Universitari Germans Trias i Pujol , Badalona, Spain
                [5] 5 Endocrinology and Nutrition Department, Institute Research and Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Barcelona, Spain
                [6] 6 General Surgery Department, Hospital Universitari Germans Trias i Pujol , Badalona, Spain
                [7] 7 Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III , Madrid, Spain
                Author notes

                Edited by: Paola Silvia Morpurgo, ASST Fatebenefratelli Sacco, Italy

                Reviewed by: Ibrahim AlZaim, Aarhus University, Denmark

                Khanyisani Ziqubu, North-West University, South Africa

                Izabela Szymczak-Pajor, Medical University of Lodz, Poland

                *Correspondence: Laura Herrero, lherrero@ 123456ub.edu ; David Sánchez-Infantes, david.sanchezi@ 123456urjc.es

                †These authors have contributed equally to this work

                Article
                10.3389/fendo.2024.1346317
                10965774
                38544694
                0e3e3287-f9ca-45ca-98f0-7ee4f0da7826
                Copyright © 2024 Reyes-Farias, Fernández-García, Corrales, González, Soria-Gondek, Martínez, Pellitero, Tarascó, Moreno, Sumoy, Medina-Gómez, Sánchez-Infantes and Herrero

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 29 November 2023
                : 23 February 2024
                Page count
                Figures: 5, Tables: 1, Equations: 1, References: 58, Pages: 11, Words: 4881
                Funding
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Instituto de Salud Carlos III (grants CP15/00106, PI17/01455, PI20/00807 to DS-I.) and the Spanish Ministry of Science and Innovation (MCIN/AEI) (grant PID2020-114953RB-C21 to LH, grant IJC2018-037142-I to RC) co-funded by the European Regional Development Fund [ERDF], the Biomedical Research Centre in Pathophysiology of Obesity and Nutrition (CIBEROBN) (Grant CB06/03/0001 to LH), the Merck Health Foundation (to LH), and the Government of Catalonia (2021SGR00367 to LH). RC is a Serra Húnter Fellow. MR-F is a recipient of a CONICYT-ANID Chile doctoral fellowship.
                Categories
                Endocrinology
                Original Research
                Custom metadata
                Obesity

                Endocrinology & Diabetes
                obesity,immunometabolism,il-16,inflammation,adipocytes
                Endocrinology & Diabetes
                obesity, immunometabolism, il-16, inflammation, adipocytes

                Comments

                Comment on this article